Complications of Intra-Arterial Chemotherapy for Retinoblastoma

References

• Shields CL, Kaliki S, Rojanaporn D, et al. Intravenous and intra-arterial chemotherapy for retinoblastoma: What have we learned? Curr Opin Ophthalmol 2012;23(3):202–209
   PubMed Web of Science ®Google Scholar
• Kivela T. The epidemiological challenge of the most frequent eye cancer: Retinoblastoma, an issue of birth and death. Br J Ophthalmol 2009;93(9):1129–1131
   PubMed Web of Science ®Google Scholar
• The Committee for the National Registry of Retinoblastoma. Survival rate and risk factors for patients with retinoblastoma in Japan. Jpn J Ophthalmol 1992;36(2):121–131
   PubMed Web of Science ®Google Scholar
• Suzuki S, Kaneko A. Management of intraocular retinoblastoma and ocular prognosis. Int J Clin Oncol 2004;9(1):1–6
   PubMedGoogle Scholar
• Schefler AC, Abramson DH. Retinoblastoma: What is new in 2007–2008. Curr Opin Ophthalmol 2008;19(6):526–534
   PubMed Web of Science ®Google Scholar
• Shields CL, Shields JA. Intra-arterial chemotherapy for retinoblastoma: The beginning of a long journey. Clin Experiment Ophthalmol 2010;38(6):638–643
   PubMed Web of Science ®Google Scholar
• Doz F. Retinoblatoma: A review. Arch Pediatr 2006;13(10):1329–1337
   PubMed Web of Science ®Google Scholar
• Jabbour P, Chalouhi N, Tjoumakaris S, et al. Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma. J Neurosurg Pediatr 2012;10(3):175–181
   PubMed Web of Science ®Google Scholar
• Abramson DH. Super selective ophthalmic artery delivery of chemotherapy for intraocular retinoblastoma: “Chemosurgery,” the first Stallard lecture. Br J Ophthalmol 2010;94(4):396–399
   PubMed Web of Science ®Google Scholar
• Nishimura S, Sato T, Ueda H, et al. Acute myeloblastic leukemia as a second malignancy in a patient with hereditary retinoblastoma. J Clin Oncol 2001;19(21):4182–4183
   PubMed Web of Science ®Google Scholar
• Reese AB, et al. The treatment of retinoblastoma by X-ray and triethylene melamine. AMA Arch Ophthalmol 1958;60(5):897–906
   PubMedGoogle Scholar
• Shields CL, et al. Intra-arterial chemotherapy for retinoblastoma: Report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol 2011;129(11):1399–1406
   PubMedGoogle Scholar
• Kiribuchi M. Retrograde infusion of anti-cancer drugs to ophthalmic artery for intraocular malignant tumors. Nihon Ganka Gakkai Zasshi 1966;70(11):1829–1833
   PubMedGoogle Scholar
• Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 2004;9(2):69–73
   PubMedGoogle Scholar
• Abramson DH, et al. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 2008;115(8):1398–1404, 1404
   PubMed Web of Science ®Google Scholar
• Inomata M, Kaneko A. Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay. Jpn J Cancer Res 1987;78(8):858–868
   PubMedGoogle Scholar
• Francis JH, et al. Carboplatin +/− topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma. PLoS One 2013;8(8):e72441
   Web of Science ®Google Scholar
• Gobin YP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: Four-year experience. Arch Ophthalmol 2011;129(6):732–737
   PubMed Web of Science ®Google Scholar
• Marr B, et al. Spontaneously resolving periocular erythema and ciliary madarosis following intra-arterial chemotherapy for retinoblastoma. Middle East Afr J Ophthalmol 2010;17(3):207–209
   PubMedGoogle Scholar
• Gobin P, Dunkel I, Brodie S, Abramson D. Intra-arterial chemotherapy (chemosurgery) in the ophthalmic artery for the treatment of retinoblastoma in children: 3 year experience. J Neurointerv Surg 2009;1(1):77–78
   Google Scholar
• Sarici A, et al. Blue toe syndrome as a complication of intra-arterial chemotherapy for retinoblastoma. JAMA Ophthalmol 2013;131(6):801–802
   PubMed Web of Science ®Google Scholar
• Hirschmann JV, Raugi GJ. Blue (or purple) toe syndrome. J Am Acad Dermatol 2009;60(1):1–20; quiz 21–2
   PubMed Web of Science ®Google Scholar
• Orbach DB, Vanderveen DK, Shah AS, Rodriguez-Galindo C. Blue toe syndrome: a complication of intra-arterial technique, not intra-arterial chemotherapy for retinoblastoma. JAMA Ophthalmol 2014 May;132(5):654
   Google Scholar
• Klumpp S, Jorge LM, Aziz-Sultan MA. Hemodynamic instability induced by superselective angiography of the ophthalmic artery. Case Rep Anesthesiol 2013;2013: 408670
   PubMedGoogle Scholar
• Abruzzo T, et al. Cerebral vasoconstriction triggered by sympathomimetic drugs during intra-atrerial chemotherapy. Pediatr Neurol 2013;48(2):139–142
   PubMed Web of Science ®Google Scholar
• Munier FL, et al. Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina 2011;31(3): 566–573
   PubMed Web of Science ®Google Scholar
• Shields CL, et al. Intra-arterial chemotherapy for retinoblastoma: Report No. 2, treatment complications. Arch Ophthalmol 2011;129(11):1407–1415
   PubMedGoogle Scholar
• Wilson MW, et al. Real-time ophthalmoscopic findings of superselective intraophthalmic artery chemotherapy in a nonhuman primate model. Arch Ophthalmol 2011;129(11):1458–1465
   PubMedGoogle Scholar
• Steinle JJ, et al. Intra-ophthalmic artery chemotherapy triggers vascular toxicity through endothelial cell inflammation and leukostasis. Invest Ophthalmol Vis Sci 2012;53(4):2439–2445
   PubMed Web of Science ®Google Scholar
• Eagle RC Jr, et al. Histopathologic observations after intra-arterial chemotherapy for retinoblastoma. Arch Ophthalmol 2011;129(11):1416–1421
   PubMedGoogle Scholar
• Muen WJ, et al. Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma. Ophthalmology 2012;119(3):611–616
   PubMed Web of Science ®Google Scholar
• Demirci H, et al. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction. Arch Ophthalmol 2003;121(8):1125–1131
   PubMedGoogle Scholar
• Bianciotto C, et al. Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma. Ophthalmology 2012;119(4):843–849
   PubMed Web of Science ®Google Scholar
• Tsimpida M, et al. Visual outcomes following intraophthalmic artery melphalan for patients with refractory retinoblastoma and age appropriate vision. Br J Ophthalmol 2013;97(11):1464–1470
   PubMed Web of Science ®Google Scholar
• Brodie SE, et al. Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Doc Ophthalmol 2009;119(1):13–22
   PubMed Web of Science ®Google Scholar